TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial
Study Details
Study Description
Brief Summary
The primary efficacy objective is to determine whether a TAVI procedure performed by experienced operators in centers without on-site cardiac surgery is noninferior to TAVI procedure performed by the same operators in centers with on-site cardiac surgery in terms of all-cause death, stroke and rehospitalization for cardiovascular cause. The primary safety objective is to demonstrate that mortality associated with periprocedural complications actionable by emergent cardiac surgery did not differ between study arms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
TRACS is an all-comer, prospective, randomized, multicenter, open-label trial with blinded adjudicated evaluation of outcomes (PROBE). The TRACS trial will involve centers without on-site cardiac surgery, but with experienced operators already performing TAVI at the referring center with on-site cardiac surgery. Thus, participating centers and their study TAVI operators must follow selective criteria for eligibility. Participants will be recruited after Heart Team indication to TAVI procedure. The eligibility of each single patient to the study MUST BE CONFIRMED and VALIDATED by unanimous decision of the Heart Team. Study patients will be randomized in a 2:1 fashion to TAVI procedure performed by the same experienced operators either in the center without on-site cardiac surgery or in the referring center with on-site cardiac surgery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: EXPERIMENTAL ARM: TAVI WITHOUT ON-SITE SURGERY After randomization, study TAVI operators of the participating center will schedule the patient for TAVI within 7-10 days in their hospital without on-site surgery |
Procedure: TAVI WITHOUT ON-SITE SURGERY
After randomization, study TAVI operators of the participating center will schedule the patient for TAVI within 7-10 days in their hospital without on-site surgery
|
| Active Comparator: CONTROL ARM: TAVI WITH ON-SITE SURGERY After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter |
Procedure: TAVI WITH ON-SITE SURGERY
After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
|
Outcome Measures
Primary Outcome Measures
- Primary efficacy endpoint [1-year]
1-year cumulative occurrence of all-cause death, stroke and hospital readmission for CV cause To test if the outcome of TAVI procedures performed by experienced operators in the center without onsite cardiac surgery is non inferior to that of TAVI procedures performed by the same team in the center with on-site cardiac surgery
- Primary safety endpoint [1-year]
To test whether mortality due to periprocedural complications actionable by emergent cardiac surgery differs between the TAVI procedures performed in the center without on-site cardiac surgery and the TAVI procedures performed by the same team in the center with on-site cardiac surgery
Secondary Outcome Measures
- Secondary efficacy endpoints [1-year]
All-cause death Cardiovascular death Myocardial infarction Hospital admission for cardiovascular cause Hospital admission for heart failure Cerebrovascular accident Ischemic stroke Hospital admission for pneumonia (± respiratory failure) Need for balloon aortic valvuloplasty for emergent condition Quality of life measured with the Eq-5D and KCCQ-12 scales Time spent on the waiting list before TAVI
- Other safety endpoints [1-year]
Cardiac tamponade Bleeding Kidney failure (requirement for renal replacement therapy) Severe aortic regurgitation (aortic regurgitation according to current guidelines) Multiorgan failure (failure of at least two organ systems) Vascular access site and access related complications Conduction disturbances and arrhythmias Endocarditis Valve thrombosis Valve malpositioning Valve embolization Ectopic valve deployment TAV-in-TAV deployment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Severe aortic stenosis
-
Indication to TAVI confirmed by the Study Heart Team
AND one of the following:
-
Inoperable due to prohibitive operative risk
-
High surgical risk as defined as STS score >8%
The presence of at least one clinical factor that, by unanimous judgment of the Study Heart
Team, compromises the benefit/risk ratio in the case of emergent cardiac surgery:
-
Porcelain aorta or severely atherosclerotic aorta
-
Frailty/Reduced physical performance
-
Cognitive impairment, dementia, or Parkinson's disease
-
Severe liver disease/cirrhosis
-
Hostile chest
-
Internal mammalian artery or other critical conduit(s) crossing midline and/or adhering to the posterior table of the sternum
-
Severe pulmonary hypertension and/or severe right ventricular dysfunction
-
Severe Chronic Obstructive Pulmonary Disease (COPD)
-
Age ≥85 years
Exclusion Criteria:
-
Unsuitable for transfemoral TAVI
-
Emergent TAVI
-
Noncardiovascular comorbidity reducing life expectancy to <1 year
-
Any factor precluding 1-year follow-up
-
Refusal informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Azienda Unità Sanitaria Locale | Bologna | Italy | 40100 |
Sponsors and Collaborators
- Azienda Usl di Bologna
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 40-2023-SPER-AUSLBO